Recent News Releases

For investor-related news, see our ASX releases here.

Month Year

Month Year

Mar 11, 2009

CSL Behring Receives Orphan-Drug Exclusivity for RiaSTAP

CSL Behring has been informed by the U.S. Food and Drug Administration (FDA) that because RiaSTAP is the first FDA-approved treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, the company is entitled to seven years of orphan-drug exclusivity.

11 Mar 2009 CSL Behring has been informed by the U.S. Food and Drug Administration (FDA) that because RiaSTAP™ is the first FDA-approved treatment of acute bleeding episodes in patients with...
Jan 16, 2009

CSL Behring Receives FDA Approval of RiaSTAP, First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency

Congenital fibrinogen deficiency is a rare, potentially life-threatening bleeding disorder that affects an estimated one person per million, with an estimated prevalence in the U.S. of approximately 300 patients.

16 Jan 2009 CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for RiaSTAP™, the first and only treatment of acute bleeding episodes in...

Show per page

Filter by Company: